Focus on advancing immunomodulating cancer treatments
The interactions between cancer tissue and a patient's individual immune system are part of a complex and hitherto insufficiently understood interplay. However, a thorough understanding of this complex orchestration of activating and suppressing signals is essential as a basis for the application, and especially the clinical advancement, of immunomodulating treatment strategies for patients with metastasising cancers.
It is precisely these multimodal immunological factors that the Christian Doppler Laboratory for Personalized Immunotherapy will be studying in order to lay the foundations for the advancement of immunomodulating treatments.
Presentations and Statements
Federal Minister for Digital and Economic Affairs of Austria
Vice Rector for Research and Innovation, Medical University of Vienna
President of the Christian Doppler Research Association (CDG)
The CD-Lab for Personalized Immunotherapy
Head of Christian Doppler Laboratory for Personalized Immunotherapy, Head of Division of Oncology, Department of Internal Medicine I, Medical University of Vienna / Vienna General Hospital
Senior-PostDoc Doppler Laboratory for Personalized Immunotherapy, Division of Oncology, Department of Internal Medicine I, Medical University of Vienna / Vienna General Hospital
Medical Director Roche Austria
The CD-Laboratory for Personalized Immunotherapy is a project of the Medical University of Vienna, the corporate partner is Roche Austria.
Christian Doppler Laboratories are financed by joint public and corporate funding. The major public funding source is the Federal Ministry for Digital and Economic Affairs of the Republic of Austria (BMDW).